Country Medical Manager - LC

Job description

At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections,  where you are valued, accepted and respected for who you are, allowing you to thrive both personally and professionally. This is how we aim to prevent, stop and cure diseases and ensure everyone has access to healthcare today and for generations to come. Join Roche, where every voice matters. The PositionPrinciple Roles & Responsibilities / Accountabilities 主要职责/责任 (Major functions of the position) （职位的首要职能） 1. Contributing with Medical Expertise (core & common): ● Medical Expertise: responsible for proactively contributing strong scientific, medical, and therapeutic area expertise within the relevant diseases informing differentiation of our pipeline and portfolio. Acting as a medical expert for the pipeline and portfolio throughout the product life cycle. ● Shape Strategy: Lead the medical part of the integrated strategy, shape a forward-thinking, scientifically sound and differentiated value story locally and communicate Roche’s contributions across key disease areas, reflecting an end-to-end business perspective that pulls through the strategy with impact. 2. Proactive Customer Engagement & Insights (core & common): ● Proactive Targeted Medical Engagement: As a medical function our ambition is to spend the majority of our time proactively engaging with external customers as partners in the integrated customer engagement strategy. The CMM serves as the scientific and medical expert, proactively engaging top-tier TAEs, and other key stakeholders in full strategic and operational alignment with other in-field roles. In the pre-launch phase it is the priority to drive proactive E2E strategies that deliver superior experience, anticipate the future and shape medical practice accordingly. In the post-launch phase the engagement continues to ensure that the right patients are treated at the right time and the engagement scope expands on unserved patient populations. In-field engagement serves as a critical component of this overarching strategy for targeted scientific engagement. It is understood that based on business needs the CMM can serve as the primary point of contact for certain customers with the ambition to drive required healthcare system changes and where feasible earlier and broader adoption of our transformative portfolio. ● Medical Partnership & Education: Establish and maintain effective peer-to-peer relationships with external stakeholders and identify/develop science-driven collaborations withTAEs. Provide current, high-quality, integrated Medical Education plan and differentiating scientific information to external customers, support the scientific training of internal teams and ensure continuous education on medical knowledge for PPoC roles. Conduct high-quality, non-promotional International/National Scientific Exchanges to disseminate relevant data, foster physician confidence and clinical endorsement based on differentiating evidence and experience. ● Insight Generation: Based on aligned goals in the franchise team, the CMM should systematically conduct insight generation initiatives for responsible disease area/indication, including designing, collecting, analyzing, and translating external scientific and clinical practice insights (including patient perspectives) into strategic actionable and differentiating recommendations for the franchise team. Insights are secured in peer to peer discussions and via targeted medical activities. One of the medical activities involves medical/scientific advisory boards as a source of insights and strategic counsel. 3. License to operate & Operational Excellence (core & common): ● Adherence to Standards: Ensure all medical activities, including customer engagements, research projects, and material co-creation, are executed in line with company policies, procedures, and the highest compliance standards. This includes strict adherence to corporate policies, ethical behavior, local regulatory requirements as well as Good Clinical Practice (GCP), Good Pharmacovigilance Practice (GVP). 4. Evidence Generation (Module Evidence Generation): CMM acts as the navigators, guiding a disease area/asset through the complexities of development, launch, and post-launch phases. Steer the organization toward its goals, ensuring that all efforts are synchronized and aligned with the overarching strategy. ● Integrated Evidence Planning: – Proactively involved in global integrated evidence plan (IEP) development in the initial stage to make sure China local practice reflected and fulfilled local regulatory and payers’ requirements to achieve market authorizations, reimbursement and value protection of our medicines/indications. – Develop the local IEP, including a comprehensive local evidence gap analysis of required value narratives for the diverse set of healthcare system stakeholders, patients and caregivers. This analysis is crucial to inform global and cross-country opportunities and identify remaining requirements for local evidence to support medical practice adoption, access and continuous value demonstration across the asset life cycle. Strategic decision making, portfolio prioritization and resource allocation is to follow accordingly. ● Evidence Strategy Implementation: Contribute directly to the local evidence strategy, proactively identifying local differentiating evidence gaps, and facilitating the development and implementation of differentiating tactics to address the prioritized gaps, specifically to ensure, maintain and broaden access to our portfolio. These differentiating tactics include leading or supporting Interventional Studies (IS), Non-Interventional Studies (NIS), externally submitted Investigator-Initiated Studies (IIS) with a relevant strategic fit, and Real-World Evidence/Data (RWE/RWD) studies, scientific projects and other activities. ● Clinical Development Support – Identify the key TAEs to provide insights into the disease burden, the patient pathway, patient needs and preferences, current treatment landscape and potential shifting in standard of care, to understand external needs and develop optimal company evidence generation strategies and action plans that are relevant for patients or society. – Collaborate closely with Clinical Operations (PDG) and Legal/Regulatory (LEG) teams to provide support for Phase I-IV clinical studies when needed. This includes partnering with PDG for site engagement such as proactive input on feasibility and strategic site selection, participating in selected SIVs providing essential medical expertise and relevant knowledge to aid in study execution in collaboration with GMCL (Global Medical Collaboration Leader) and / or other functions as applicable per local agreement. For selected sites (global most valuable customers) take an active role in the OneRoche (g/pRED, PD, GPS, Affiliate, PT, Diagnostics) E2E holistic customer experience loop. Ensure that key insights from investigators, study coordinators and nurses are brought into the strategic planning of “how to go to market” and the local IEP gap analysis. 5. Focusing on Patient Impact and driving the value story in the HTA process (Module HTA) ● Maximizing HTA Value: Contribute scientific and medical expertise to local Health Technology Assessment (HTA) submissions and interactions, ensuring critical appraisal mindset on our data packages with good statistical understanding and by discussing the evidence for its transferability to the real-world healthcare setting. CMM should lead a holistic evidence generation strategy to support market access to articulate the differentiating value story of our innovations in the local context to secure patient access. – CMM ensures early insights are used to generate local IEP/local gap analysis so data generation initiatives support the HTA value package loc